Trials / Terminated
TerminatedNCT06285097
A Study of PF-07820435 as a Single Agent and in Combination in Participants With Advanced Solid Tumors
A PHASE 1 DOSE ESCALATION AND EXPANSION STUDY TO EVALUATE SAFETY, TOLERABILITY, PHARMACOKINETIC, PHARMACODYNAMIC, AND ANTITUMOR ACTIVITY OF PF-07820435 AS MONOTHERAPY AND IN COMBINATION IN PARTICIPANTS WITH ADVANCED SOLID TUMORS
- Status
- Terminated
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 9 (actual)
- Sponsor
- Pfizer · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study aims to evaluate the safety, and early signals of anti-tumor activity of PF-07820435 when administered alone (Part 1A) or in combination with sasanlimab (Part 1B; Part 2) in patients with selected advanced or metastatic solid tumors. Part 1 will be dose-finding and Part 2 of the study will further evaluate PF-07820435 at the recommended dose for combination expansion in patients with selected advanced solid tumors.
Conditions
- Neoplasms
- Non-small-cell Lung Cancer
- Melanoma
- Squamous Cell Carcinoma of the Head and Neck
- Renal Cell Carcinoma
- Urothelial Carcinoma
- Colorectal Carcinoma
- Ovarian Carcinoma
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | PF-07820435 | immune agonist |
| BIOLOGICAL | Sasanlimab | A monoclonal antibody that blocks the interaction between PD-1 and PD-L1/L2 |
Timeline
- Start date
- 2024-02-08
- Primary completion
- 2025-01-03
- Completion
- 2025-02-13
- First posted
- 2024-02-29
- Last updated
- 2025-09-17
Locations
10 sites across 3 countries: United States, Japan, Puerto Rico
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06285097. Inclusion in this directory is not an endorsement.